PRAX Praxis Precision Medicines, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
13:23
Aug 21
Aug 21
Consensus biotech longs round-trip as regrossing starts
Degrossing used these crowded biotech longs as the ATM to fund short covering; with regrossing already starting, gross rebuild should push these names back up as flows round-trip.
MED
12:58
Aug 17
Aug 17
Reports largest aggregate Q2 fund holdings
"Reports largest aggregate Q2 2026 holdings across 95 specialist funds based on 13F filings, no directional view."
MED
12:53
Aug 17
Aug 17
Reports widest ownership across specialist funds
"Reports widest Q2 2026 ownership across 95 specialist funds based on 13F filings, no directional view."
MED
12:31
Aug 17
Aug 17
Notes large aggregate Q2 fund holdings
Notes the stock is among the largest aggregate Q2 holdings across 93 funds based on 13F filings.
MED
17:11
Aug 10
Aug 10
The author defends their binary event call accuracy by listing past winners and losers.
The author defends their binary event call accuracy by listing past winners and losers, but frames it as a track record defense rather than a current position or forward call.
LOW
13:13
Jun 21
Jun 21
Buy the "hot zone" biotech names (3–9 months post positive data) as the author's historical M&A.
Buy the "hot zone" biotech names (3–9 months post positive data) as the author's historical M&A timing framework shows this is the window where acquirers with pre-committed capital execute; sector M&A wave across radiopharmaceuticals, MASH, IBD, and obesity validates the pattern is active.
MED
00:55
Jun 21
Jun 21
The tweet maps biotech M&A timing and independent name catalysts since the XBI bottom.
The tweet maps biotech M&A timing and independent name catalysts since the XBI bottom, but it is a factual research summary without explicit author positions or forward calls.
LOW
11:13
Jun 17
Jun 17
Author reflects on a prior bullish call on biotech bottom and specific catalysts like QURE.
Author reflects on a prior bullish call on biotech bottom and specific catalysts like QURE approval and ABVX acquisition, but the tweet is a retrospective check-in rather than a fresh forward position.
11:49
Jun 02
Jun 02
Premarket movers include mixed Mag 7 performance, semiconductor sector rallies on AI growth.
Premarket movers include mixed Mag 7 performance, semiconductor sector rallies on AI growth, and notable individual stock moves on earnings, downgrades, and corporate announcements.
03:06
Jun 02
Jun 02
Baird reduced its price target on Praxis Precision Medicines to 400 dollars from 433 dollars.
17:44
May 07
May 07
The author lays out a concentrated long biotech portfolio on a down XBI day.
The author lays out a concentrated long biotech portfolio on a down XBI day, highlighting ABVX as a major position and listing other names under consideration, reflecting a bullish sector outlook despite short-term losses.
HIGH
About PRAX Analyst Coverage
Buzzberg tracks PRAX (Praxis Precision Medicines, Inc.) across 3 sources. 1 bullish vs 0 bearish calls from 3 analysts. Sentiment: predominantly bullish (9%). 11 total trade ideas tracked. Latest voices: seedy19tron, zerohedge, FirstSquawk.